Sodium picosulfate is a contact stimulant laxative used as a treatment for constipation or to prepare the large bowel before colonoscopy or surgery. It is available as a generic medication. In technical terms it is an orally administered prodrug that is converted by colonic bacterial enzymes to an active metabolite that stimulates enteric nerves and increases intestinal fluid secretion, producing a laxative effect. Typical formulations include sachets for oral solution and ready-to-use liquids, often combined with osmotic agents for bowel cleansing. The usual adult oral dose for occasional constipation is in the low milligram range and bowel preparation regimens vary by product; onset of effect depends on formulation and dose. Key pharmaceutical attributes include low systemic absorption, predictable concentration-response in the colon, stability under recommended storage conditions, and amenability to routine quality control by HPLC for assay and related substances.
Parent: Bisacodyl/ Picosulfate
Parent: Picosulfate
Parent: Picosulfate
Parent: Picosulfate
Parent: Picosulfate
Parent: Picosulfate
Typical manufacturer specification items for sodium picosulfate raw material and finished formulations include an assay range of approximately 98.0 to 102.0 percent on a dried basis, related substances measured by validated HPLC with limits such as individual known degradation products not more than 0.5 percent, unidentified impurities not more than 0.1 percent, and total impurities generally controlled to not exceed 1.0 percent; residual solvents are controlled to accepted ICH limits for the solvent class present, water content is typically kept below 0.5 percent, and heavy metals are restricted to low ppm levels consistent with pharmacopeial expectations. Identification is confirmed by IR and HPLC retention time, and stability monitoring focuses on the principal degradants and total impurity profile to ensure product remains within specified limits throughout shelf life.
Sodium picosulfate is used to relieve short term constipation and to induce bowel evacuation as part of bowel cleansing regimens prior to colonoscopy or colorectal surgery.
Human data are limited; because systemic exposure is low it is sometimes used when clinically necessary, but it should be taken only after discussion with a healthcare professional who can weigh potential benefits and risks.
Onset varies by formulation and dose; oral doses commonly produce bowel action within about 6 to 12 hours, while formulations intended for rapid action or rectal administration can work faster.
Both are stimulant laxatives with similar mechanisms and efficacy; choice depends on clinical context, patient tolerance, formulation preference and local protocol. Bisacodyl may be preferred for some rapid-acting indications and sodium picosulfate is often used in bowel prep regimens.
